Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition or treatment. Clinical decisions must always be made based on individual patient circumstances, local guidelines, and the clinician's judgment.

---

WHO Classification Of Anemia In Children

Overview

• Definition: Anemia is a condition characterized by a reduced number of red blood cells or a reduced concentration of hemoglobin in the blood, leading to a diminished oxygen-carrying capacity. The World Health Organization (WHO) defines anemia in children based on age-specific hemoglobin (Hb) concentration thresholds below which an individual is considered anemic. These thresholds are critical for public health monitoring and clinical diagnosis.

  • WHO Hemoglobin Thresholds for Anemia in Children (at sea level):
    • Children 6–59 months: Hemoglobin < 11.0 g/dL
    • Children 5–11 years: Hemoglobin < 11.5 g/dL
    • Children 12–14 years: Hemoglobin < 12.0 g/dL
  • WHO Severity Classification (commonly applied to Iron Deficiency Anemia for children 6-59 months):
    • Mild Anemia: Hb 10.0 – 10.9 g/dL
    • Moderate Anemia: Hb 7.0 – 9.9 g/dL
    • Severe Anemia: Hb < 7.0 g/dL
  • Note: These values may need adjustment for individuals living at high altitudes, as physiological acclimatization to lower oxygen pressure leads to increased hemoglobin concentrations. For every 1000m (approx. 3300 feet) above sea level, add approximately 0.3-0.5 g/dL to the threshold.

• Epidemiology: Anemia in children, primarily iron deficiency anemia, remains a major global public health problem, particularly in low- and middle-income countries.

  • Prevalence: Globally, over 40% of children aged 6 months to 5 years are anemic. The highest prevalence is observed in South Asia and Africa.
  • Impact: Contributes significantly to child mortality and morbidity, impaired cognitive and motor development, reduced physical activity, and increased susceptibility to infections.
  • Causes: Iron deficiency is the most common cause, but other significant contributors include malaria, helminth infections, other nutritional deficiencies (e.g., folate, vitamin B12, vitamin A), chronic inflammation, and genetic disorders (e.g., thalassemia, sickle cell disease).

• Classification: While the WHO classification primarily focuses on defining anemia by Hb levels and severity, the underlying etiological classification is essential for targeted management. Anemia can be broadly classified by:

  • Morphology (MCV):
    • Microcytic (MCV < 80 fL for adults, age-adjusted for children): Common in iron deficiency, thalassemia, lead poisoning, anemia of chronic disease.
    • Normocytic (MCV 80-100 fL, age-adjusted): Common in acute blood loss, anemia of chronic disease, renal failure, aplastic anemia, mixed deficiencies.
    • Macrocytic (MCV > 100 fL, age-adjusted): Common in folate/B12 deficiency, liver disease, hypothyroidism, myelodysplastic syndromes.
  • Etiology (Pathophysiology):
    • Decreased Red Blood Cell Production (e.g., nutritional deficiencies, bone marrow failure, chronic disease).
    • Increased Red Blood Cell Destruction (hemolysis) (e.g., hemoglobinopathies, G6PD deficiency, autoimmune hemolytic anemia).
    • Blood Loss (acute or chronic).

Pathophysiology

• Mechanism: Anemia arises from an imbalance in red blood cell (RBC) production, destruction, or loss.

  • Decreased Production:
    • Nutritional Deficiencies: Insufficient intake or absorption of essential nutrients (iron, folate, vitamin B12, vitamin A) required for erythropoiesis. Iron deficiency is paramount as iron is crucial for hemoglobin synthesis.
    • Bone Marrow Failure: Conditions like aplastic anemia, leukemia, or myelodysplastic syndromes impair the bone marrow's ability to produce healthy RBCs.
    • Anemia of Chronic Disease/Inflammation (ACD/ACI): Chronic infections (e.g., HIV, TB), autoimmune diseases, or malignancies lead to elevated inflammatory cytokines (e.g., hepcidin), which impair iron absorption and utilization, and suppress erythropoiesis.
    • Renal Disease: Decreased erythropoietin production by kidneys.
  • Increased Destruction (Hemolysis):
    • Inherited: Hemoglobinopathies (e.g., sickle cell disease, thalassemias), red cell membrane defects (e.g., hereditary spherocytosis), red cell enzyme defects (e.g., G6PD deficiency, pyruvate kinase deficiency).
    • Acquired: Autoimmune hemolytic anemia, drug-induced hemolysis, microangiopathic hemolytic anemia, severe infections (e.g., malaria, sepsis).
  • Blood Loss:
    • Acute: Trauma, severe epistaxis, gastrointestinal bleeding.
    • Chronic: Hookworm infection, Meckel's diverticulum, inflammatory bowel disease, cow's milk protein-induced enteropathy in infants.

• Risk Factors:

  • Nutritional:
    • Inadequate intake of iron-rich foods (meat, fortified cereals).
    • Exclusive breastfeeding beyond 6 months without iron supplementation/complementary foods.
    • Early introduction of cow's milk before 12 months (poor iron source, can cause GI bleeding).
    • Rapid growth spurts (infancy, adolescence).
    • Pica (ingestion of non-food items).
    • Maternal iron deficiency during pregnancy.
  • Infectious:
    • Malaria (hemolysis, dyserythropoiesis).
    • Helminthic infections (e.g., hookworm: chronic blood loss).
    • Recurrent infections (contribute to anemia of chronic disease).
  • Socioeconomic/Environmental:
    • Poverty and food insecurity.
    • Poor sanitation leading to increased infections.
    • Exposure to lead.
  • Genetic/Congenital:
    • Family history of anemia or hemoglobinopathies (e.g., thalassemia, sickle cell trait).
    • Prematurity or low birth weight (reduced iron stores).
    • Chronic medical conditions (e.g., chronic kidney disease, inflammatory bowel disease, congenital heart disease).

• Protective Factors:

  • Adequate dietary intake of iron-rich foods (heme iron from animal sources, non-heme iron from plants combined with vitamin C).
  • Iron fortification of staple foods.
  • Delayed umbilical cord clamping (increases iron stores at birth).
  • Appropriate timing of introduction of iron-fortified complementary foods from 6 months of age.
  • Deworming programs in endemic areas.
  • Malaria prevention and control measures (e.g., insecticide-treated nets, chemoprophylaxis).
  • Access to clean water and sanitation.
  • Public health campaigns promoting balanced nutrition and early detection of anemia.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Often non-specific, especially in mild to moderate anemia.
  • Pallor (paleness of skin, conjunctiva, nail beds, palms, oral mucosa).
  • Fatigue, lethargy, poor exercise tolerance.
  • Irritability, poor concentration.
  • Shortness of breath (dyspnea) on exertion.
  • Headache, dizziness.
  • Pica (craving for non-food items like dirt, ice, starch) – specific to iron deficiency.
• Early Signs:
  • Subtle pallor.
  • Reduced playfulness or activity level.
  • Increased fatigue, requiring more naps.
  • Poor appetite.
• Advanced Signs: Reflect more severe anemia (Hb < 7 g/dL) or prolonged duration.
  • Pronounced pallor (often described as "waxy").
  • Tachycardia, flow murmur (hyperdynamic circulation).
  • Exertional dyspnea, even at rest in severe cases.
  • Signs of heart failure (cardiomegaly, hepatomegaly, edema, gallop rhythm) in very severe or prolonged anemia.
  • Glossitis (sore, smooth tongue), angular stomatitis, cheilosis (cracked lips).
  • Koilonychia (spoon-shaped nails) – specific to chronic iron deficiency.
  • Splenomegaly (can suggest hemolytic anemia or chronic infection like malaria).
  • Jaundice (suggests hemolytic anemia).
  • Growth retardation and developmental delay.
• Atypical Presentations:
  • Behaviors like hyperirritability or extreme lethargy in infants.
  • Sudden collapse or syncope due to severe anemia.
  • Specific symptoms related to the underlying cause (e.g., neurological symptoms in B12 deficiency, bone pain in leukemia, recurrent infections in aplastic anemia).

Physical Examination

• Inspection:
  • Pallor: Assess conjunctiva (pull down lower eyelid), nail beds, palms (especially creases), oral mucosa, and tongue. Compare to examiner's hand.
  • Skin: Jaundice (hemolysis), petechiae/purpura (marrow failure, DIC), chronic skin lesions (chronic disease).
  • Hair: Sparse or brittle hair.
  • Nails: Koilonychia (spooning).
  • Growth: Assess height and weight for age, looking for stunting or wasting.
  • Facial features: Maxillary hyperplasia, frontal bossing (e.g., severe thalassemia).
• Palpation:
  • Lymph nodes: Generalized lymphadenopathy (infection, malignancy).
  • Abdomen: Splenomegaly (hemolytic anemia, malaria, leukemia), hepatomegaly (heart failure, severe hemolysis, liver disease).
  • Bones: Tenderness (malignancy, osteomyelitis).
• Special Tests:
  • Cardiovascular: Auscultate for flow murmurs (often systolic, loudest at the left sternal border), gallop rhythm, signs of heart failure.
  • Neurological: Assess developmental milestones, reflexes (peripheral neuropathy in B12 deficiency), cognitive function.

Diagnostic Approach

History Taking

• Key Questions:
  • Dietary History: Detailed 24-hour recall, specific intake of iron-rich foods (red meat, fortified cereals), cow's milk intake (volume, age of introduction), vitamin C intake.
  • Growth and Development: Has the child been meeting milestones? Any recent growth faltering?
  • Symptoms of Anemia: Fatigue, pallor, shortness of breath, pica, irritability, poor appetite.
  • Bleeding History: Epistaxis, gum bleeding, hematuria, bloody stools (melena/hematochezia), heavy menstrual bleeding in adolescent girls.
  • Infection History: Recurrent infections, history of malaria, hookworm exposure, HIV/TB risk.
  • Family History: Anemia, jaundice, gallstones, splenectomy (hemoglobinopathies, hereditary spherocytosis), chronic diseases.
  • Medications/Exposures: Chronic medications, lead exposure, recent drug use.
  • Birth History: Prematurity, low birth weight, maternal iron status during pregnancy, complications at birth (e.g., feto-maternal hemorrhage).
  • Geographical Location/Travel History: Endemic areas for malaria or parasitic infections.
• Red Flags:
  • Severe pallor with signs of circulatory compromise (tachycardia, poor perfusion).
  • Signs of heart failure (tachypnea, hepatomegaly, edema).
  • Fever with pallor (suggests infection, sepsis, or malignancy).
  • Bleeding symptoms (petechiae, purpura, severe epistaxis).
  • Jaundice with pallor (suggests acute hemolysis).
  • Significant developmental regression or neurological deficits.

Laboratory Tests

• First-Line:

  • Complete Blood Count (CBC):
    • Hemoglobin (Hb): Confirms anemia based on WHO age-specific thresholds.
    • Mean Corpuscular Volume (MCV): Classifies anemia morphologically (microcytic, normocytic, macrocytic).
    • Red Cell Distribution Width (RDW): Elevated in iron deficiency anemia (anisocytosis).
    • Mean Corpuscular Hemoglobin (MCH): Correlates with MCV.
    • Mean Corpuscular Hemoglobin Concentration (MCHC): Reduced in hypochromic anemias.
    • Platelet Count and White Blood Cell (WBC) Count with Differential: Assess for pancytopenia (marrow failure), thrombocytosis (inflammation, IDA), leukocytosis/leukopenia (infection, malignancy).
  • Peripheral Blood Smear:
    • Evaluate red cell morphology (microcytes, hypochromia, poikilocytes, spherocytes, target cells, sickle cells, nucleated RBCs).
    • Assess platelet and white cell morphology and numbers.
    • Look for parasites (e.g., malaria trophozoites).
  • Reticulocyte Count: Indicates bone marrow response to anemia.
    • Low reticulocytes: Suggests impaired production (e.g., nutritional deficiency, bone marrow suppression).
    • High reticulocytes: Suggests hemolysis or acute blood loss.

• Confirmatory (Based on First-Line Findings and Clinical Suspicion):

  • Iron Studies:
    • Serum Ferritin: Best indicator of body iron stores. Low ferritin (<12-30 ng/mL, age-specific reference ranges apply) confirms iron deficiency. Note: Ferritin is an acute phase reactant, so it can be elevated in inflammation masking iron deficiency.
    • Serum Iron: Total iron in serum (variable).
    • Total Iron-Binding Capacity (TIBC): Elevated in iron deficiency, reduced in chronic disease.
    • Transferrin Saturation (TSAT): (Serum Iron / TIBC) x 100. Low (<16%) in iron deficiency.
  • Inflammatory Markers: CRP, ESR – helpful if ferritin is ambiguous (high or normal) to assess for anemia of chronic disease.
  • Vitamin B12 and Folate Levels: If macrocytic anemia or neurological symptoms are present.
  • Hemoglobin Electrophoresis/HPLC: To screen for hemoglobinopathies (e.g., sickle cell disease, thalassemia).
  • G6PD Screening: If hemolytic anemia is suspected, especially in regions with high prevalence or after exposure to oxidant drugs/foods.
  • Direct Antiglobulin Test (DAT/Coombs Test): If autoimmune hemolytic anemia is suspected.
  • Stool Studies: For occult blood, ova and parasites (e.g., hookworm).
  • Lead Levels: If environmental exposure is suspected.
  • Renal Function Tests: BUN, Creatinine – if kidney disease is suspected.
  • Thyroid Function Tests: TSH, Free T4 – if hypothyroidism is suspected.
  • Bone Marrow Aspiration and Biopsy: If aplastic anemia, leukemia, or other severe bone marrow disorders are suspected (e.g., pancytopenia).

• Monitoring:

  • Repeat CBC with Hb and MCV: To assess response to therapy (e.g., iron supplementation). Typically, repeat Hb in 4 weeks after starting iron.
  • Reticulocyte Count: May show an early peak (reticulocyte crisis) 5-10 days after starting iron, indicating effective erythropoiesis.
  • Ferritin: To confirm repletion of iron stores after 3-6 months of therapy.

Imaging

• Recommended: Imaging is generally not first-line for routine anemia diagnosis but may be indicated based on suspected underlying causes.
  • Chest X-ray: For cardiomegaly in severe heart failure due to anemia.
  • Abdominal Ultrasound: To assess for splenomegaly or hepatomegaly if not clearly palpable, or to investigate organomegaly of unclear etiology. Also for kidney structure in chronic renal disease.
• Advanced:
  • Echocardiography: In severe symptomatic anemia or signs of heart failure to assess cardiac function and identify any structural abnormalities.
  • Gastrointestinal Endoscopy/Colonoscopy: To identify sources of chronic GI bleeding if suspected and other tests are negative.
  • MRI: Rarely needed, possibly for bone marrow evaluation in complex hematological disorders or neurological involvement in B12 deficiency.

Management

Acute Management

• Immediate:
  • Assess ABCs (Airway, Breathing, Circulation): Stabilize vital signs.
  • Oxygen supplementation: If hypoxic or in respiratory distress.
  • Intravenous access: For fluid resuscitation and blood product administration.
• Stabilization:
  • Fluid Resuscitation: For hypovolemia in acute blood loss. Use isotonic crystalloids (e.g., normal saline or Ringer's lactate) if blood products are not immediately available.
  • Blood Transfusion (Packed Red Blood Cells): Indicated for severe symptomatic anemia or very low Hb levels to prevent complications.
    • General WHO/Clinical Guidelines for Transfusion in Children:
      • Hb < 4 g/dL: Transfuse regardless of symptoms.
      • Hb 4-6 g/dL: Transfuse if symptomatic (e.g., heart failure, respiratory distress, shock, altered mental status) or if rapid decline is expected. Consider transfusion based on clinical judgment for asymptomatic children in this range, especially if associated with critical illness.
      • Hb 6-7 g/dL: Transfuse if symptomatic or critically ill (e.g., severe sepsis, shock, chronic heart disease with decompensation).
      • Hb > 7 g/dL: Generally, transfusion is not indicated unless there is active ongoing bleeding, severe cardiopulmonary compromise, or specific conditions like sickle cell crisis.
    • Dosage: Typically 10-15 mL/kg of packed red blood cells (PRBCs) over 2-4 hours, aiming for a target Hb level. Monitor for signs of fluid overload, especially in severely malnourished children. For severe anemia with heart failure, transfuse slowly (e.g., 2-3 mL/kg/hour) and consider diuretics.
• Emergency:
  • Manage active bleeding (e.g., surgical intervention, clotting factor replacement).
  • Treat severe underlying infections (e.g., severe malaria, sepsis).
  • Manage complications like heart failure or shock aggressively.

Chronic Management

• Pharmacological:

  • Iron Supplementation (for Iron Deficiency Anemia):
    • Therapeutic Dose (Elemental Iron): 3-6 mg/kg/day, typically divided into 1-2 doses. For severe IDA or poor response, up to 6 mg/kg/day may be used.
      • Common formulations: Ferrous sulfate (20% elemental iron), ferrous gluconate (12% elemental iron), ferrous fumarate (33% elemental iron).
      • Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption, but if GI upset occurs, can be given with food.
      • Administer with Vitamin C (e.g., orange juice) to enhance absorption.
      • Duration: Continue for at least 3 months after Hb normalizes to replenish iron stores (often total 3-6 months).
    • Prophylactic Dose (Elemental Iron):
      • Term infants (not exclusively breastfed): 1 mg/kg/day from 4-6 months until 12 months.
      • Preterm infants: 2-4 mg/kg/day from 1 month until 12 months.
      • Adolescent girls: 30-60 mg elemental iron daily for 3 months, then intermittently.
    • Parenteral Iron: Reserved for severe malabsorption, significant intolerance to oral iron, non-compliance, or severe chronic kidney disease. Requires careful monitoring due to risk of hypersensitivity reactions.
  • Folate Supplementation: If folate deficiency is diagnosed or suspected (e.g., chronic hemolytic anemia like sickle cell disease, where folate demand is high).
    • Dose: 1 mg daily (or 5 mg daily for chronic hemolytic states).
  • Vitamin B12 Supplementation: For confirmed B12 deficiency (intramuscular injections initially, then oral).
  • Specific treatments for underlying causes:
    • Antimalarials for malaria.
    • Antihelminthics (e.g., albendazole, mebendazole) for parasitic worm infections.
    • Immunosuppression for autoimmune hemolytic anemia or aplastic anemia.
    • Erythropoiesis-stimulating agents (ESAs) for anemia of chronic kidney disease.
    • Chelation therapy for iron overload in conditions like thalassemia.

• Non-pharmacological:

  • Dietary Education: Promote consumption of iron-rich foods (red meat, poultry, fish, legumes, fortified cereals) and vitamin C-rich foods.
  • Improved Hygiene and Sanitation: To prevent parasitic infections.
  • Malaria Control: Insecticide-treated bed nets, prompt diagnosis, and treatment.
  • Management of Chronic Diseases: Optimize control of underlying inflammatory or chronic conditions.

• Monitoring:

  • Follow-up Hb:
    • After starting iron: Check Hb and reticulocytes at 2-4 weeks to confirm response. Expect an increase of 1-2 g/dL in Hb over 4 weeks for iron deficiency.
    • Monthly/quarterly until Hb normalizes.
    • At the end of therapy: Check Hb and ferritin to confirm repletion of iron stores.
  • Clinical assessment: Monitor for improvement in symptoms, growth, and development.

Treatment Algorithms

• First-Line (for most common anemia in children - Iron Deficiency Anemia):

  1. Diagnose Anemia (WHO criteria): Hb < 11.0 g/dL (6-59 months), < 11.5 g/dL (5-11 years), < 12.0 g/dL (12-14 years).
  2. Assess Severity: Mild, Moderate, Severe (Hb < 7.0 g/dL requires urgent assessment for transfusion).
  3. Confirm Iron Deficiency: Low MCV, low ferritin, high RDW, appropriate clinical context. In resource-limited settings, empiric iron therapy may be initiated for non-severe anemia based on clinical suspicion due to high prevalence of IDA.
  4. Exclude other causes: If atypical presentation or poor response.
  5. Oral Iron Supplementation: 3-6 mg elemental iron/kg/day for 3-6 months.
  6. Dietary Counseling: Emphasize iron-rich foods and vitamin C.
  7. Follow-up: Hb check at 2-4 weeks (expect reticulocytosis, Hb increase). Continue monitoring until Hb normalizes and for 3-6 months thereafter.

• Second-Line (if poor response to first-line or other causes suspected):

  1. Re-evaluate Diagnosis: Is it truly iron deficiency? Consider malabsorption, chronic blood loss, non-compliance, co-existing deficiencies, or another underlying cause (e.g., thalassemia trait, anemia of chronic disease).
  2. Investigate Non-responders: Check iron studies again, inflammatory markers, B12/folate, hemoglobin electrophoresis, stool for occult blood/parasites.
  3. Address Malabsorption: If confirmed, consider higher oral doses, different iron salts, or parenteral iron.
  4. Manage Chronic Blood Loss: Identify and treat source.
  5. Address Anemia of Chronic Disease: Treat underlying chronic infection/inflammation.
  6. Switch to Parenteral Iron: If severe malabsorption or intolerance.

• Refractory Cases:

  1. Comprehensive Hematological Workup: Refer to a pediatric hematologist for in-depth evaluation. This may include bone marrow biopsy, advanced genetic testing, or specialized functional assays.
  2. Consider Rare Causes: Aplastic anemia, myelodysplastic syndromes, congenital dyserythropoietic anemias, very rare enzyme deficiencies.
  3. Ongoing Supportive Care: Regular transfusions if necessary, with iron chelation to prevent iron overload. Management of complications.

Complications

• Common:
  • Fatigue, weakness, reduced physical activity.
  • Impaired cognitive function and academic performance.
  • Behavioral problems (irritability, attention deficits).
  • Increased susceptibility to infections.
• Serious:
  • Cardiac Complications: High-output cardiac failure, cardiomyopathy, arrhythmias (especially with Hb < 4 g/dL).
  • Growth and Developmental Retardation: Long-term impact on physical growth and neurodevelopment.
  • Increased Risk of Prematurity and Low Birth Weight: If anemia persists into adolescence and pregnancy.
  • Increased Morbidity and Mortality: Especially in severe anemia or when co-existing with severe infections like malaria.
• Long-term:
  • Irreversible neurocognitive deficits if severe anemia occurs during critical periods of brain development (first 2 years of life).
  • Chronic fatigue and reduced quality of life.
  • Increased healthcare utilization.

Prognosis

• Factors: Prognosis largely depends on the underlying cause, severity, timing of diagnosis, and effectiveness of treatment.
  • Good Prognosis: Iron deficiency anemia, if diagnosed early and treated appropriately, has an excellent prognosis with complete resolution of symptoms and reversal of most complications.
  • Variable Prognosis: Anemias due to chronic diseases, nutritional deficiencies (other than iron), or some hemolytic conditions.
  • Poor Prognosis: Severe hereditary anemias (e.g., transfusion-dependent thalassemia major, severe aplastic anemia, certain leukemias) often require lifelong specialized care and may have significant morbidity and mortality.
• Survival: Varies greatly with the etiology. Severe anemia is a major contributor to child mortality globally. Early detection and intervention, particularly with iron deficiency and malaria, significantly improve survival rates.
• Quality of Life: Chronic anemia, even if not life-threatening, can significantly impair a child's quality of life due to persistent fatigue, cognitive impairment, and increased susceptibility to infections. Prompt and adequate treatment can restore normal quality of life in many cases.

Prevention

• Primary: Aimed at preventing the initial occurrence of anemia.
  • Nutritional Interventions:
    • Promote Breastfeeding: Exclusive for the first 6 months.
    • Appropriate Complementary Feeding: Introduction of iron-rich complementary foods (fortified cereals, pureed meats) from 6 months of age.
    • Iron Fortification: Fortification of staple foods (flour, rice, oil) with iron and other micronutrients at a national level.
    • Dietary Diversification: Education on consumption of diverse diets rich in iron, vitamin C (enhances iron absorption), and other micronutrients.
    • Delayed Umbilical Cord Clamping: At least 1-3 minutes after birth, if feasible, to increase infant iron stores.
  • Iron Supplementation Programs:
    • Universal Prophylactic Iron: For infants and young children in high-risk areas.
    • Intermittent Iron and Folic Acid Supplementation: For school-aged children and adolescent girls in endemic areas (e.g., weekly iron/folate tablets).
  • Infection Control:
    • Malaria Prevention: Insecticide-treated bed nets, indoor residual spraying, intermittent preventive treatment in infants (IPTi) and pregnant women (IPTp).
    • Deworming Programs: Mass drug administration of antihelminthics (e.g., albendazole) in areas endemic for soil-transmitted helminths.
    • Improved Water, Sanitation, and Hygiene (WASH): To reduce incidence of diarrheal diseases and parasitic infections.
    • Immunization: Prevention of infections that can cause or exacerbate anemia.
• Secondary: Early detection and prompt intervention to prevent progression.
  • Anemia Screening Programs: Regular hemoglobin screening for at-risk groups (e.g., infants, young children, pregnant women) as per national guidelines.
  • Early Diagnosis and Treatment: Prompt diagnosis and management of infections (e.g., malaria, severe bacterial infections) and underlying chronic diseases.
• Tertiary: Preventing complications and improving outcomes in those already affected.
  • Appropriate Management: Adherence to treatment protocols for anemia and its underlying causes.
  • Monitoring: Regular follow-up to ensure treatment efficacy and address recurrence.
  • Nutritional Rehabilitation: For children with severe malnutrition and anemia.
  • Management of Chronic Conditions: Optimal management of conditions like thalassemia, sickle cell disease, or chronic kidney disease to mitigate anemia.

Special Populations

• Pediatric: The entire classification and discussion are specific to children. Key considerations within the pediatric population include:
  • Infants (0-12 months): High risk of iron deficiency due to rapid growth, depletion of prenatal iron stores (around 4-6 months in term infants), and reliance on breast milk (low iron content) or unfortified formula.
  • Toddlers (1-3 years): Continued rapid growth, picky eating, and high cow's milk intake can increase risk.
  • Adolescents: Rapid growth spurts, poor dietary habits, and onset of menstruation in girls increase iron requirements and risk of deficiency.
  • Premature Infants: Born with lower iron stores, require earlier and higher doses of prophylactic iron supplementation.
• Geriatric: Not directly applicable to the WHO classification of anemia in children. Anemia in the elderly often relates to chronic disease, nutritional deficiencies, or myelodysplastic syndromes, with different diagnostic and management considerations.
• Pregnancy: Not directly applicable to the WHO classification of anemia in children. Anemia in pregnancy is also defined by WHO (Hb <11.0 g/dL) and is a significant global health issue with implications for maternal and fetal health, requiring specific screening and iron/folate supplementation guidelines.
• Comorbidities:
  • Chronic Kidney Disease (CKD): Anemia is common due to reduced erythropoietin production. Managed with erythropoiesis-stimulating agents (ESAs) and iron supplementation.
  • Inflammatory Bowel Disease (IBD): Anemia due to chronic inflammation (anemia of chronic disease), malabsorption (iron, B12, folate), and chronic blood loss. Requires careful management of IBD activity, iron supplementation (often IV), and other micronutrients.
  • Infectious Diseases (e.g., HIV, TB): Contribute to anemia of chronic disease, nutritional deficiencies, or direct bone marrow suppression. Management includes treating the infection and addressing nutritional needs.
  • Genetic Disorders (e.g., Sickle Cell Disease, Thalassemia): These are primary causes of hemolytic or ineffective erythropoiesis and require specialized lifelong management, including regular transfusions, iron chelation, and sometimes stem cell transplant.

Clinical Pearls

• Diagnostic:
  • Pallor is a late sign: By the time pallor is obvious, anemia is often moderate to severe.
  • MCV is age-dependent: Always use age-specific reference ranges for MCV when interpreting CBC in children.
  • Ferritin can be misleading: An elevated ferritin in an inflamed child does not rule out concurrent iron deficiency. Consider TSAT or a therapeutic trial of iron.
  • Empiric Iron Trial: In high-prevalence settings, a 1-month trial of oral iron for children with non-severe anemia and no other obvious cause may be considered if iron studies are unavailable or expensive. Look for reticulocyte response and Hb rise.
  • Don't forget the smear: A peripheral blood smear is invaluable and can provide crucial clues that a CBC alone cannot (e.g., sickle cells, spherocytes, blast cells, parasites).
• Treatment:
  • Compliance is key: Educate parents on the importance of consistent iron administration and potential side effects (constipation, dark stools).
  • Duration of iron: Continue iron supplementation for at least 3 months after Hb normalizes to replenish stores.
  • Transfusion threshold: While Hb < 7 g/dL is a common threshold, clinical symptoms (e.g., cardiac decompensation, respiratory distress, shock) should always guide transfusion decisions, even at higher Hb levels.
  • Underlying cause: Always investigate and address the underlying cause of anemia; simply treating the anemia without addressing the root cause will lead to recurrence.
• Pitfalls:
  • Over-reliance on Hb alone: Missing the underlying cause or other co-existing deficiencies.
  • Inadequate duration of iron therapy: Leading to rapid relapse once therapy is stopped prematurely.
  • Ignoring non-responders: Failure to investigate poor response to iron therapy can delay diagnosis of more serious conditions.
  • Unnecessary transfusions: Transfusions carry risks; ensure clear indications before administering.
  • Overlooking high-altitude adjustment: Failing to account for altitude can lead to misdiagnosis of anemia.

Recent Updates

• Guidelines:
  • WHO Guidelines (2016 onwards): Emphasize the integrated approach to anemia prevention and control, including nutrition-specific interventions (e.g., daily iron supplementation for pregnant women, iron-folic acid supplementation for adolescents, delayed cord clamping) and nutrition-sensitive interventions (e.g., deworming, malaria control, water and sanitation improvements).
  • Recent Pediatric Guidelines: Reinforce the importance of universal screening for anemia in infants and young children, often at 9-12 months of age, and targeted screening for high-risk groups.
• Evidence:
  • Improved understanding of Hepcidin: Its role as the master regulator of iron metabolism helps explain anemia of chronic disease and informs diagnostic approaches (e.g., soluble transferrin receptor can be more reliable than ferritin in inflammation).
  • Micronutrient interactions: Growing evidence on the interplay of various micronutrients (e.g., vitamin A, riboflavin, copper, zinc) in iron metabolism and erythropoiesis.
  • Intermittent vs. Daily Iron: Further studies on the effectiveness and side-effect profile of intermittent iron supplementation in children and adolescents, showing it can be effective with fewer side effects, potentially improving compliance.
• Controversies:
  • Optimal timing and dosage of universal iron supplementation: Balancing the benefits of prevention against potential risks (e.g., increased oxidative stress, gut dysbiosis in some contexts, or masking other conditions).
  • Role of genetic screening: Debate on routine screening for common hemoglobinopathies (e.g., alpha thalassemia trait) in certain populations before iron supplementation to avoid iron overload in non-iron deficient individuals.
  • Use of non-invasive screening tools: Development and validation of point-of-care devices for Hb measurement in resource-limited settings.

Key References

• Guidelines:
  • World Health Organization (WHO): Guidelines on the Prevention and Management of Iron Deficiency in Infants and Young Children. (Numerous relevant publications on anemia, iron, and nutrition.)
  • WHO: Guideline: Daily iron supplementation in infants and children. Geneva, World Health Organization; 2016.
  • American Academy of Pediatrics (AAP): Clinical Practice Guideline for the Diagnosis and Management of Iron Deficiency Anemia in Infants and Young Children (0-3 Years of Age). Pediatrics. 2010;126(5):1040-1050. (While dated, it is a foundational reference).
  • National Heart, Lung, and Blood Institute (NHLBI): Guidelines for the Management of Sickle Cell Disease.
• Studies:
  • Landmark epidemiological studies on the global burden of anemia (e.g., Global Burden of Disease Study data).
  • Randomized controlled trials on the efficacy of iron supplementation programs in various settings.
• Reviews:
  • Comprehensive reviews in major pediatric and hematology journals (e.g., Blood, New England Journal of Medicine, Lancet, Pediatrics, British Journal of Haematology).
  • Standard pediatric textbooks (e.g., Nelson Textbook of Pediatrics, Rudolph's Pediatrics).

---

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition or treatment. Clinical decisions must always be made based on individual patient circumstances, local guidelines, and the clinician's judgment.